NewsCase
.com
Financial Intelligence
Market Analysis
Defense & Aerospace
AI & Tech
Banking & Finance
Crypto
European Stocks
🌐
EN
中文
Menu
Market Analysis
Defense & Aerospace
AI & Tech
Banking & Finance
Crypto
European Stocks
Search NewsCase
Home
Pharma & Biotech
Pharma & Biotech
AI & Quantum Computing
Analysis
Anime
Asian Markets
Automotive & E-Mobility
Banking & Insurance
Bitcoin
Blockchain
Bonds
Ocugen’s 2027 Readout and a $255 Million Licensing Ceiling Are Two Very Different Kinds of Promise
Healthcare
October 27, 2026
Moderna’s Pipeline Widens Beyond Melanoma, but Each Study Stands on Its Own
Analysis
October 27, 2026
Moderna’s Melanoma Win Is Clinically Real. Citi’s Sell Call Says the Economics Aren’t.
Analysis
October 26, 2026
Moderna’s Melanoma Win Is Real. The Economics of Making It Are the Open Question.
Analysis
October 24, 2026
Ocugen Puts a Date on the Calendar, but 2027 Data Still Carries the Weight
Earnings
October 22, 2026
BioNTech Hands Gilead the Chemo Slot in ROSETTA Breast-01 — A Trial Design, Not a Verdict
Analysis
October 22, 2026
Moderna’s October Script Has Two Storylines, and Only One of Them Is Clinical
Analysis
October 21, 2026
Moderna’s Calendar Is Crowded, but Only Two Entries Carry Real Weight
Analysis
October 20, 2026
1
2
3
...
106
Page 2 of 106